ASHA-624 / Asha Therap - LARVOL DELTA

Advancium Health Network Catalyzes Research on an Innovative SARM1 Inhibitor in a Rare Eye Disease (PRNewswire) - "Advancium Health Network...has awarded two major grants to accelerate research into a potential treatment for Autosomal Dominant Optic Atrophy (ADOA)—the most common hereditary optic neuropathy....Advancium's funding will support two parallel preclinical studies focused on ASHA-624, a novel first-in-class molecular glue targeting SARM1 designed by Asha Therapeutics....One study will be led by Dr. Thomas Schwarz and Dr. Chen Ding at Harvard Medical School/Boston Children's Hospital....The second study, led by Asha Therapeutics, will evaluate ASHA-624 in a different ADOA mouse model."

Financing • Preclinical • Ophthalmology

First-in-human trial of ALS therapy ASHA-624 expected in early 2025 (ALS News Today) - "A newly awarded grant from the ALS Association will support Asha Therapeutics‘ work to advance ASHA-624, a small molecule being developed for amyotrophic lateral sclerosis (ALS), into a first-in-human clinical trial that’s expected to begin early next year."

New trial • Amyotrophic Lateral Sclerosis

Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics’ Founders to Company’s Scientific Advisory Board (Businesswire) - "Asha Therapeutics...announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS)."

Financing • Amyotrophic Lateral Sclerosis

Asha Therapeutics Announces the Nomination of a Novel Intra-Molecular Glue Development Candidate ASHA-624 as a Disease Modifying Therapeutic for Amyotrophic Lateral Sclerosis (Businesswire) - "Asha Therapeutics...announced today the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with additional indications in Chemotherapy-Induced Peripheral Neuropathy (CIPN), Glaucoma, and traumatic brain and spinal cord injuries."

Pipeline update • Amyotrophic Lateral Sclerosis • CNS Disorders • Glaucoma • Neuralgia • Ophthalmology • Pain • Peripheral Neuropathic Pain